SCHEMBL27318793

SCHEMBL27318793

CCNc1cc(Nc2cccc(CN)c2)ncn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.67
JAK3 P52333 4/20 0.45
TNNI3K Q59H18 3/20 0.44
MEN1 O00255 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
CCNT1 O60563 3/20 0.43
CDK9 P50750 3/20 0.43
CFD P00746 2/20 0.42
ERBB3 P21860 2/20 0.42
MAP4K4 O95819 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42
CCND1 P24385 1/20 0.42
CDK2 P24941 1/20 0.42
ABL2 P42684 1/20 0.42
GSK3A P49840 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27338332 0.85 EGFR (0.49) EGFRJAK3TNNI3KMEN1NPC1
SCHEMBL27401062 0.85 EGFR (0.49) EGFRJAK3TNNI3KMEN1NPC1
SCHEMBL27332161 0.85 JAK3 (0.58) EGFRJAK3MEN1NPC1RAB9A
SCHEMBL27408584 0.85 EGFR (0.52) EGFRJAK3TNNI3KMEN1NPC1
SCHEMBL374504 0.84 EGFR (0.64) EGFRJAK3TNNI3KMEN1NPC1
SCHEMBL27338330 0.83 MEN1 (0.50) EGFRTNNI3KMEN1NPC1RAB9A
SCHEMBL27332169 0.83 EGFR (0.51) EGFRJAK3MEN1NPC1RAB9A
SCHEMBL27523685 0.83 EGFR (0.51) EGFRJAK3MAP4K4
SCHEMBL27345372 0.83 EGFR (0.46) EGFRJAK3TNNI3KMEN1NPC1
SCHEMBL27337227 0.83 JAK3 (0.50) EGFRJAK3TNNI3KMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1047778-C Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them THOMAE GMBH DR K (DE) 1999-12-29 CN disclosed